Date Title Description PDF
08 May 2024 On P&L The Company releases the press release related to the first three months of 2024 financial results Download
08 May 2024 On P&L The Company releases the first three months 2024 financial results presentation Download
25 Apr 2024 On business and financial situation ROVI announces agreement to manufacture pre-filled syringes Download
27 Feb 2024 On P&L The Company releases the press release related to the full year 2023 financial results. Download
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download

Pages

Date Title Description PDF
18 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 11 August and 17 August 2023 Download
11 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 August and 10 August 2023 Download
03 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 Download
28 Jul 2023 On business and financial situation ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® Download
05 Jul 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2023 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages